Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. (2022)
Attributed to:
Development of an ovine polyclonal immunoglobulin therapy against COVID-19.
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.antiviral.2022.105332
PubMed Identifier: 35533779
Publication URI: http://europepmc.org/abstract/MED/35533779
Type: Journal Article/Review
Volume: 203
Parent Publication: Antiviral research
ISSN: 0166-3542